Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and plays an active role in supporting the growth of his companies. Mr. Wolf's start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel biocompatible polymers and acquired by Medtronic; and EluSys Therapeutics (co-founder and founding CEO), a biodefense company focused on the development of Anthim® antibody therapeutic, an approved medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law, and his B.A. from the University of Chicago where he graduated with honors in economics.
Joe Payne is the President and Chief Operating Officer at Scorpius BioManufacturing. He has over two decades of biopharma industry experience, including at both biopharmaceutical companies and CDMOs, including companies like Teva Pharmaceuticals (Manager, Operations & Risk Assessment), Alcami Corporation (VP, Quality & Regulatory), and Tergus Pharma (VP, Quality & Compliance).
He joined Scorpius in 2023 as VP of Quality and Regulatory Affairs. He has participated in 40+ regulatory inspections and has extensive knowledge of global regulatory agency requirements. Joe has a broad range of experience in drug development, operational execution, and executive management in addition to QC and compliance.
In his role as President and COO, he oversees quality, manufacturing, process sciences, and commercial operations.
Joe earned a B.S. in Chemistry from Hampden-Sydney College in Virginia.
Brian O’Mara is the Vice President, Process Sciences at Scorpius. He is responsible for the process and analytical development and scale-up related activities of biologics, including technology transfer, process characterization, and facility fit to support the manufacture of clinical grade biologics.
Brian has 24+ years of industrial biotechnology experience in the downstream process development of early- and late-stage protein therapeutics from mammalian and microbial expression systems. He also has extensive experience in the development of protein conjugates, including antibody drug conjugates (ADCs), bi-specifics, and PEGylated molecules.
He is proficient in scale-up and technology transfer, CDMO management, process characterization, preparation and oversight of PPQ campaigns, and associated CMC regulatory filings.
Ania Szymanska is the Vice President, Quality & Regulatory Affairs at Scorpius BioManufacturing. She brings over twenty years of leadership and management experience in Quality Control, Quality Assurance, and Compliance at pharmaceutical and biotech companies.
Ania joined Scorpius from Marker Therapeutics, Inc. where she was Vice President of Quality. While at Marker, she built the Quality Management Systems and played a critical role in the design, construction, and qualification of their state-of-the-art cell therapy GMP manufacturing facility and Quality Control laboratories. Prior to Marker, Ms. Szymanska served as Director of Quality Control for Bellicum Pharmaceuticals, Inc. from May 2016 to March 2019, where she developed Quality Control department and was responsible for aseptic facility qualification. She also served as Quality Validation Specialists of Opexa Therapeutics, Inc. from August 2015 to March 2016 and in roles of increasing responsibility at Woodfield Pharmaceutical, LLC (formerly Pernix Manufacturing, LLC) from 2008 to August 2015, most recently as Director of Microbiology.
Ms. Szymanska earned an M.S. in Microbiology from the University of Warsaw.